Introduction
Intravenous loop diuretics are the cornerstone for the management of acute decompensated heart failure (ADHF). However, their use can be associated with changes in renal function, neurohormonal activation, and diuretic resistance.
1 -5 As a result, ultrafiltration (UF) for fluid removal in ADHF may be an attractive alternative in this setting. Unlike loop diuretics, UF removes iso-osmotic filtrate from the blood bypassing the more traditional early resulting from slower-than-projected study enrolment. 10 As a result, uncertainty remains regarding the clinical utility of UF in heart failure and it is not strongly endorsed by the current heart failure practice guidelines.
11,12
We hypothesized that the lack of superiority of UF over pharmacological therapy on the magnitude of decongestion, reported in the primary CARRESS-HF analysis, 13 was effected by substantial dropout or crossover of participants in the UF arm. To test this hypothesis, we performed a per-protocol analysis of the original CARRESS-HF participants. Second, we sought to use this analytic framework to better understand the direct effect of UF on clinical biomarkers and neurohormonal activation.
Methods

Study cohort
The CARRESS-HF trial was conducted within the National Heart, Lung, and Blood Institute National Institute of Health-sponsored Heart Failure Clinical Trials Network. The CARRESS-HF protocol was approved by the Institutional Review Board at each site, and written informed consent was obtained from all study participants prior to randomization and this study complies with the Declaration of Helsinki.
Briefly, the CARRESS-HF trial was conducted between 2008 and 2012 at 22 clinical sites in the United States. This trial sought to determine the effectiveness of UF as a primary decongestive therapy in comparison to a pharmacological stepwise urine output-guided diuretic dosing algorithm in patients hospitalized with persisting congestion in the setting of ADHF >0.3 mg/dL rise in serum creatinine within the prior 6 weeks or up till 10 days after admission for heart failure. 14 Of the 188 participants, 94 were randomly assigned to the UF arm and 94 were assigned to the pharmacological arm. The primary findings have been previously published. 13 
Study design
In order to better understand the direct clinical effects of UF-mediated fluid removal in comparison to pharmacological fluid removal, we sought to perform a per-protocol analysis on the original CARRESS-HF dataset. The inclusion to the per-protocol comparison groups was defined as follows: (i) participants randomized to the pharmacological arm who only had recorded urine output at 24 h, by 48 h, by 72 h, and by 96 h; and (ii) participants assigned to the UF arm who had recorded UF output at 24 h, 48 h, 72 h, and 96 h. If, at any time, participants initially assigned to the pharmacological arm had UF output recorded, they were excluded from the analysis. Similarly, participants initially assigned to the UF arm with no collected UF output by 24 h but had collected UF output by 48 h, or without UF output throughout 96 h were excluded from the analysis.
Definitions
The pharmacological arm was an active comparator that included an aggressive, urine output-guided, diuretic titration protocol, which sought a comparable fluid removal to UF. Intravenous loop diuretics were titrated daily to target 3-5 L of urine output per day with stipulations for additional supplementation with thiazide diuretics, vasoactive or inotropic medications. 15 The estimated UF rate (mL/h) for each 24 h period was calculated as the total UF output (mL) 
Outcomes
The cardiorenal biomarkers were collected at baseline and 96 h and analysed in a central laboratory and included serum creatinine, plasma renin activity, aldosterone, cystatin C, and N-terminal pro B-type natriuretic peptide (NT-proBNP) at baseline and 96 h. All other bloodwork including serum creatinine measured at 24, 48, and 72 h was analysed by the local laboratories. Cumulative fluid output was the summation of daily urine output for 96 h for the pharmacological arm and the summation of both UF and urine output for 96 h for the UF arm. Relative weight to baseline was calculated as [weight (lbs)/baseline weight (lbs)] x 100. There were two 60-day composite endpoints: (i) death, heart failure hospitalization, or unscheduled emergency department or clinic visit; and (ii) death, any hospitalization, or unscheduled emergency department or clinic visit.
Statistical analysis
Continuous variables were expressed as median (25th-75th percentile) and categorical variables as number (%) and were compared via the Kruskal-Wallis and Pearson's Chi-Square tests, respectively. Mixed effects models assuming unequal variance compared the association of serial measures of cumulative fluid loss, net fluid loss, relative weight to baseline, serum creatinine, blood urea nitrogen (BUN), serum sodium, serum potassium, and serum bicarbonate between the pharmacological and UF arms from baseline to 96 h. For this analysis, each treatment arm became sequentially smaller every 24 h period corresponding to individuals that remained on their assigned treatment arm. In addition to determining the association of treatment arm on the serial parameters, the mixed effects models determined whether there were interactions with time. The Kaplan-Meier method and log-rank tests were used to compare cumulative event rates between individuals that remained in their per-protocol treatment arm by 24 h for each 60-day composite endpoint. A sensitivity analysis excluding participants assigned to the UF arm who also received i.v. loop diuretics was conducted. All analyses were completed on Stata 13.1 software (StataCorp LP, College Station, TX, USA).
Results
Per-protocol cohort
Of the 188 initial randomly assigned participants, 94 were assigned to the pharmacological arm and 94 were assigned to the UF arm. Of those assigned to the pharmacological arm, 92 remained on-treatment (i.v. diuretics) by 24 h, 90 by 48 h, 86 by 72 h, and 76 by 96 h. In contrast, there was more dropout in the UF arm. Of those assigned to the UF arm, 71 remained on-treatment (UF) by 24 h, 66 by 48 h, 43 by 72 h, and 30 by 96 h. Figure 1 displays the daily evolution of the per-protocol cohort highlighting sequential dropout with reasons for those that left their respective treatment arm. While there were 22 individuals who left the UF arm for the achievement of optimal volume status over 96 h, this was counterbalanced by participants experiencing either i.v. line-related complications or UF mechanical complications (i.e. vascular access failure or filter clogging, 34 episodes recorded) and more hypotension or clinical instability, increased creatinine, and evidence of volume depletion than participants in the pharmacological arm. Although the CARRESS-HF study design sought to target a UF fluid removal rate of 200 mL/h, 14 the estimated hourly UF rates per 24 h period where much more variable and lower than intended. The estimated UF rates were 83 (46-109) mL/h; 140 (83-178) mL/h; 107 (32-178) mL/h; and 70 (21-115) mL/h for each sequential 24 h period from baseline to 96 h, respectively.
Baseline characteristics
The baseline characteristics of participants who remained on-treatment through the initial 24 h are shown in Table 1 There were no significant differences in age or male sex between the two treatment arms. Otherwise, there was a higher prevalence of non-ischemic heart failure aetiology in the pharmacological arm (P = 0.04), and higher serum creatinine (P = 0.02), lower serum sodium (P = 0.03) and higher NT-proBNP in (P = 0.04) in the UF arm. Lastly, there were no differences in pre-randomization medication use. The characteristics stratified by participants who remained on their assigned treatment arm vs. those who had left are shown in the supplementary material online, Table S1 . While CARRESS-HF originally sought to compare a pure i.v. loop diuretic-based fluid removal strategy to pure UF-based fluid removal strategy, there were individuals who received i.v. loop diuretics in the UF arm. Although this was a minority, there were fewer on i.v. loop diuretics with relatively lower doses in those that remained in the per-protocol UF arm through 96 h. Intravenous loop diuretic use was 32% (n/N = 23/71) at 24 h, 9% (n/N = 6/66) at 48 h, 5% (n/N = 2/43) at 72 h, and 7% (n/N = 2/30) at 96 h. Interestingly, there was 100% adherence (n/N = 92/92) to i.v. loop diuretic use by 24 h in the pharmacological arm, but this too, reduced sequentially until 96 h. For the pharmacological arm, i.v. loop diuretic use was 97% (n/N = 87/90) at 48 h, 88% (n/N = 76/86) at 72 h, and 75% (n/N = 57/76) at 96 h. Inotrope use was rare at 15% (n/N = 14/92) in the pharmacological arm and 8% (n/N = 6/71) in the UF arm (P = 0.19). Unlike the results from the intention-to-treat analysis, 13 UF was associated with higher serial cumulative fluid loss (P = 0.003), higher net fluid loss (P = 0.001), and a greater relative reduction in weight over time (P = 0.02) than pharmacological therapy. Figure 3 highlights the impact of each treatment arm on serial serum laboratory testing through 96 h. In comparison to the pharmacological protocol, UF was associated with significantly higher serum creatinine levels by 72 h (P-interaction = 0.001) and 96 h (P-interaction <0.001) after being on treatment. There was a similar association with UF and higher BUN levels at 72 h (P-interaction = 0.02) and 96 h (P-interaction = 0.001). After 24 h, UF therapy was associated with lower serum sodium levels over time at 48 h (P-interaction = 0.001), 72 h (P-interaction = 0.003), and 96 h (P-interaction <0.001). In contrast, pharmacological therapy was significantly associated with a reduction in potassium over time, which became evident at 48 h and persisted at 72 h and 96 h (P-interaction <0.001 for all). Interestingly, individuals assigned to the pharmacological arm had higher serum bicarbonate levels over time than did the UF arm at 24 h (P-interaction = 0.001), 48 h, 72 h, and 96 h (P-interaction <0.001 for all). Although there were no differences in serial haemoglobin levels over time, individuals in the pharmacological arm had a higher haemoglobin by 96 h (P-interaction <0.001). In a sensitivity analysis excluding participants assigned to the UF arm receiving concomitant i.v. loop diuretics, all findings were comparable (supplementary material online, Figures S1-S3 and Table S2 ). Table 2 highlights the absolute changes in clinical characteristics and cardiorenal biomarkers from baseline to 96 h for those that remained on-treatment through 96 h. There was no difference in change in symptoms as measured by dyspnoea or global visual assessment scales and no difference in mean arterial pressure change or heart rate change between arms. While there were no differences in aldosterone, cystatin C, or NT-proBNP level changes from baseline to 96 h between the two treatment arms, UF was associated with an increase in plasma renin activity by 96 h (P = 0.04).
Comparison of serial clinical parameter changes
Clinical parameter changes through 96 hours
Long-term composite endpoints
For those that remained on-treatment by 24 h, there were 68 deaths, heart failure hospitalizations, or unscheduled emergency department or clinic visits by 60 days; and 90 deaths, any hospitalizations, or unscheduled emergency department or clinic visits by 60 days. Kaplan-Meier estimates for the two 60-day composite endpoints are shown in Figure 4 . There was no significant difference in the incidence of either endpoint with respect to those that remained on-treatment by 24 h. For the composite endpoint of death, heart failure hospitalization, or unscheduled emergency department or clinic visits, there was no difference in the cumulative incidence between the two arms in those who remained at 48 h . (P = 0.67), 72 h (P = 0.98), and 96 h (P = 0.64). For the composite endpoint of death, any hospitalization, or unscheduled emergency department or clinic visits, there was no difference in the cumulative incidence between the two arms in those who remained at 48 h (P = 0.13), 72 h (P = 0.38), and 96 h (P = 0.63).
Discussion
Findings from this per-protocol analysis of the CARRESS-HF cohort highlight some of the short-term clinical implications of UF therapy and contrast the physiological differences between extracorporeal fluid removal and pharmacologically-mediated decongestion. When accounting for dropout, UF was associated with more efficient decongestion in comparison to an aggressive urine output-guided diuretic-based pharmacological protocol. This effect was tempered, however, by heightened cardiorenal and neurohormonal manifestations of rapid volume removal, including higher serum creatinine, higher BUN, lower sodium levels, and increased plasma renin activity during UF therapy. In parallel, these results also support that the evolution of a 'contraction alkalosis' during pharmacological decongestion is the result of a loop diuretic effect rather than aggressive volume depletion. After mitigating the differential bias resulting from substantial dropout in the UF arm from CARRESS-HF, these findings support the increased efficiency of UF-mediated decongestion in ADHF. This contrasts to the primary findings of the original CARRESS-HF intention-to-treat analysis, which showed no difference in the weight loss component of the primary endpoint by 96 h. 13 Superior volume removal with UF compared to diuretics has been described in prior studies in ADHF, 6 -10 and may extend them for the management of persistent congestion in the setting of worsening renal function. In contrast to the Ultrafiltration versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Congestive Heart Failure (UNLOAD) 7 and the Continuous Ultrafiltration for Congestive Heart Failure (CUORE) trials, 8 which showed a significant reduction in rehospitalization with UF vs. standard care, or the AVOID-HF trial, 10 which suggested a trend towards an increase in time to first heart failure event (rehospitalization or unscheduled visit), no improvement in clinical outcomes was found in this study. clinical outcomes. This concept is supported by the observation that 60-day event rates in CARRESS-HF were higher than any previous trial of ADHF. Fundamentally, the mechanical removal of an iso-osmotic filtrate during UF differs greatly from diuretic-mediated decongestion, which blocks sodium resorption in the loop of Henle and results in hypotonic urine. Mechanistic studies have suggested a limited impact of short-term UF on glomerular function and renal rise in serum creatinine during treatment. Another explanation, consistent with criticisms of CARRESS-HF, 21 may be related to the rapidity and amount of fluid removal as the cause for worsening renal function. However, the average daily UF rates for those on-treatment were highly variable with median values more comparable or even lower than other UF studies. 7, 8, 10 Similar to these findings (but not analysed by a repeated measures analysis), there was a trend towards higher serum creatinine in the UF arm by 72 h of UNLOAD suggesting this might not be a trial design-specific phenomenon. 7 As previously suggested, 22 these findings support that the logical explanation for rise in serum creatinine in the face of UF-mediated decongestion might be a relative imbalance in aggressive plasma volume removal that is disproportionately higher to the plasma refill rate from the interstitial space, leading to a drop in effective arterial blood volume. This is well-described in traditional haemodialysis, 23 and linked to inter-dialytic hypotensive episodes. Although, UF rates can be 5-10 times higher in haemodialysis than for UF in ADHF where care is made to prevent haemodynamic instability. Reflective of this, UF stoppages for hypotension were rare in this study (n = 3) and changes in mean arterial pressure were comparable for both per-protocol treatment arms. However, the evolution of lowered serum sodium levels and higher plasma renin activity, which may translate into heightened angiotensin II and increased arginine vasopressin levels, may be indicative of this process. Indeed, serum sodium levels might be reflective of complex renal interplay between dilution or depletion. 24 But when encountered in UF, the physiology might be more reflective of too rapid of an isotonic fluid removal superseding the ability of extracellular interstitial sodium to replenish the intravascular space. As more evidence of volume depletion, the urinary composition of patients with UF may be more hypotonic than those on loop diuretics. 25 The heightened plasma renin activity in the UF arm is therefore not surprising in the face of an elevated BUN and lower serum sodium, 26 which might be concomitantly indicative of heightened renin-angiotensin-aldosterone axis activation (which also triggers thirst 27 ) in the face of decreased effective arterial blood volume and decreased sodium delivery to the distal nephron sensed by the juxtaglomerular cells and macula densa, respectively. 28 Although appealing, whether a slower UF rate or more patient-customized UF rate titration might translate into a more 'gentle' form of decongestion is unknown and should be the subject of future study. An additional finding from this analysis was that the evolution of a metabolic alkalosis during decongestion is likely a direct manifestation of loop diuretic use and not related to volume removal (what has been referred to as a 'contraction alkalosis'). Consistent with other cohorts, UF was relatively inert to serum potassium and bicarbonate levels, 6 -8,19 ,20 despite more aggressive volume removal than the loop diuretic-based pharmacological arm. Indeed, there is biological rationale for the disconnect between the evolution of hypovolaemia and metabolic alkalosis. Murine models of 'contraction alkalosis' suggest that chloride homeostasis, not sodium homeostasis, is the volume-independent mediator of this acid-base abnormality. 29 Furthermore, human models of chloride depletion generated by sodium restriction in combination with loop diuretic usage (two common therapies for ADHF) generate a metabolic alkalosis, and epidemiologic studies of ADHF have suggested that loop diuretic usage is associated with serial decrements in serum chloride levels during decongestion. 30, 31 The results of this study should be interpreted in the context of limitations inherent to its design. These findings are a result of a per-protocol analysis on the primary CARRESS-HF study cohort, and in comparison to the main intention-to-treat analysis, which preserves randomization, causality cannot be proven. However, an advantage of per-protocol analyses is that they may provide more direct evidence of the biological effect of the therapies. Despite the initial trial design, 14 a significant percentage of patients assigned to the UF arm received loop diuretics at each time point, which might have confounded the comparison. However, the findings of this analysis were largely unchanged when excluding participants in the UF arm that received i.v. loop diuretics (supplementary material online, Figures S1-S3 and Table S2 ). Serum albumin, total protein, haematocrit, and chloride were not collected limiting the determination of haemoconcentration and the impact of loop diuretics on increased bicarbonate. In addition, the data presented in Table 2 were not collected serially, limiting information from patients remaining in the cohort by 96 h. Daily changes in non-diuretic, non-i.v. therapies were not collected and the impact they would have had on these outcomes is uncertain. However, the impact of unbalanced medication adjustments between the two arms may have been be unlikely. At the time of discharge, there were no significant differences in renin-angiotensin system blocker use (42% vs. 34%, P = 0.28) or beta-blocker use (83% vs. 78%, P = 0.39), for the pharmacological arm and UF arm, respectively, but mineralocorticoid receptor antagonist use was more prevalent in the pharmacological arm (27% vs. 10%, P = 0.01). Lastly, the CARRESS-HF study was not powered to determine long-term clinical outcomes and statistical comparison was limited by confounding, but it is intriguing that especially given this high-risk cohort and high incidence of poor post-discharge clinical outcomes there was no prognostic benefit of UF over pharmacological care, findings which differ from those of other studies involving UF in ADHF suggesting that ADHF patients with acute cardiorenal syndrome are at especially high risk for adverse clinical outcomes, and congestion may not be the primary driver of event rates. 
Conclusion
Unlike the primary analysis, results from this per-protocol analysis of the CARRESS-HF trial demonstrate that UF is associated with greater decongestion in ADHF. Vascular access and mechanical issues related to aquapheresis limited the clinical application of this therapy, and those that remained on UF experienced rise in serum creatinine and heightened neurohormonal activation. There was also no significant difference in long-term outcomes between participants in the UF and pharmacological arms, which calls into question the prognostic relevance of UF-mediated rise in serum creatinine. This analysis also supports the hypothesis that mechanical fluid removal in ADHF may induce an imbalance in plasma volume removal and plasma refill rate. Lastly, these findings also suggest that the evolution of a metabolic alkalosis during decongestion with loop diuretics is a consequence of those pharmacological agents and not solely due to intravascular volume depletion.
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